Five Factor Model Treatment for Borderline Personality Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Coordinator
- Phone Number: 859-562-1570
- Email: tipslab@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-diagnosis of borderline personality disorder (BPD)
Exclusion Criteria:
- diagnosed psychological conditions that would be better addressed by alternative treatments
- previously received more than 5 sessions of cognitive behavioral therapy in the past 5 years
- concurrent psychotherapy
- medication instability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Immediate Treatment
Participants in this group will receive the intervention immediately.
|
The study treatment will take place across 18-sessions.
The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons [long and short-term consequences] of tolerating emotions, engaging in prosocial behavior, and delaying gratification).
Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing).
Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies.
All sessions will last for 60 minutes in duration.
|
|
Experimental: Waitlist/Delayed Treatment
Participants in this group will receive the intervention after an 18-week wait.
|
The study treatment will take place across 18-sessions.
The first session will involve psychoeducation regarding BPD.The next two sessions with include exercises drawn from Behavioral Activation (i.e., identification of value-based goals) and Motivational Interviewing (i.e., pros and cons [long and short-term consequences] of tolerating emotions, engaging in prosocial behavior, and delaying gratification).
Next, patients will receive 5 sessions of cognitive interventions (i.e., cognitive reappraisal related to situations/emotions, schema related to relationships, 5 sessions of behavior change skills (i.e., acting opposite to emotion-driven urges, exposure, assertiveness training), and 5 sessions of mindfulness skills (i.e., nonjudgmental emotion awareness, compassion training, urge surfing).
Finally, treatment will conclude with 2 sessions of Relapse Prevention strategies.
All sessions will last for 60 minutes in duration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Anxiety Symptoms
Time Frame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
|
Anxiety symptoms will be measured using the Overall Anxiety Severity and Interference Scale (OASIS).
This is a self-report measure in which scores range from 0-20; higher scores indicate more severe anxiety symptoms.
|
12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
|
|
Change in Depressive Symptoms
Time Frame: 12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
|
Depressive symptoms will be measured using the Overall Depression Severity and Interference Scale (ODSIS).
This is a self-report measure in which scores range from 0-20; higher scores indicate more severe anxiety symptoms.
|
12 weeks (baseline, week 1, week, 2, week, 3.....week 12)
|
|
Change in clinician-rated borderline personality disorder symptoms
Time Frame: 44 weeks (baseline, post-treatment/waitlist, 6 month follow-up)
|
Change in borderline personality disorder symptoms will be measured using Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) - clinician-rated version.
Scores range from 0-36; higher scores indicate greater severity of borderline personality disorder symptoms
|
44 weeks (baseline, post-treatment/waitlist, 6 month follow-up)
|
|
Change in patient-reported borderline personality disorder symptoms
Time Frame: 18 weeks (week 1[baseline for immediate treatment condition, post-waitlist for delayed treatment condition], week, 2, week 3, week, 4.....week 18)
|
Change in borderline personality disorder symptoms will be measured using Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) - self-report version.
Scores range from 0-36; higher scores indicate greater severity of borderline personality disorder symptoms
|
18 weeks (week 1[baseline for immediate treatment condition, post-waitlist for delayed treatment condition], week, 2, week 3, week, 4.....week 18)
|
|
Change in clinician-rated clinical severity
Time Frame: 44 weeks (baseline, post-treatment/waitlist, 6 month follow-up)
|
Clinical severity will be measured using the Diagnostic Interview for Anxiety, Mood, and Obsessive Compulsive and Related Neuropsychiatric Disorders (DIAMOND) dimensional clinician ratings.
Scores range from 1-7; higher scores indicate greater severity.
|
44 weeks (baseline, post-treatment/waitlist, 6 month follow-up)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shannon Sauer-Zavala, University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 60042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.